Reducing and controlling metabolic active tumor volume prior to CAR T-cell infusion can improve survival outcomes in patients with large B-cell lymphoma

Reducing and controlling metabolic active tumor volume prior to CAR T-cell infusion can improve survival outcomes in patients with large B-cell lymphoma

Abstract Bridging therapy before CD19-directed chimeric antigen receptor (CAR) T-cell infusion is frequently applied in patients with relapsed or refractory Large B-cell lymphoma (r/r LBCL). This study aimed to assess the influence of quantified MATV and MATV-dynamics, between pre-apheresis (baselin...

Full description

Bibliographic Details
Main Authors: Kylie Keijzer, Janneke W. de Boer, Jaap A. van Doesum, Walter Noordzij, Gerwin A. Huls, Lisanne V. van Dijk, Tom van Meerten, Anne G. H. Niezink
Format: Article
Language:English
Published: Nature Publishing Group 2024-03-01
Series:Blood Cancer Journal
Online Access:https://doi.org/10.1038/s41408-024-01022-w

Internet

https://doi.org/10.1038/s41408-024-01022-w

Similar Items